Login / Signup

Spironolactone to increase natriuresis in congestive heart failure with cardiorenal syndrome.

Frederik Hendrik VerbruggePieter MartensKoen AmelootVeerle HaemelsJoris PendersMatthias DupontW H Wilson TangWalter DroognéWilfried Mullens
Published in: Acta cardiologica (2018)
Spironolactone use upfront in AHF patients at high risk for cardiorenal syndrome is safe and increases natriuresis.
Keyphrases
  • heart failure
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • case report
  • patient reported outcomes
  • acute heart failure